Silexion Therapeutics Files 8-K on Warrants

Ticker: SLXNW · Form: 8-K · Filed: Nov 27, 2024 · CIK: 2022416

Sentiment: neutral

Topics: warrants, disclosure, corporate-action

Related Tickers: SLXN

TL;DR

SLXN filed an 8-K detailing warrant terms - $1.15 exercise price.

AI Summary

Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on November 27, 2024, reporting on warrants exercisable for ordinary shares at $1.150 per share. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and trades on NASDAQ under the ticker SLXN.

Why It Matters

This filing provides an update on the terms of exercisable warrants, which could impact the company's capital structure and shareholder dilution.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of warrant information and does not indicate immediate financial distress or significant operational changes.

Key Numbers

Key Players & Entities

FAQ

What is the total number of warrants outstanding?

The filing does not specify the total number of warrants outstanding.

When do these warrants expire?

The filing does not state the expiration date of the warrants.

What is the reason for the name change from Biomotion Sciences to Silexion Therapeutics Corp?

The filing states the date of the name change (20240506) but does not provide the reason.

Are there any specific conditions attached to the exercise of these warrants?

The filing mentions warrants exercisable for ordinary shares at an exercise price of $1.150 per share, but does not detail other specific conditions.

What is the par value of Silexion Therapeutics Corp's ordinary shares?

The par value of Silexion Therapeutics Corp's ordinary shares is $0.00001 per share.

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-27 06:01:18

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On November 27, 2024, Silexion Therapeutics Corp posted to its website (https://silexion.com/) an updated corporate presentation. A copy of the presentation is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this report, including the information in the corporate presentation, furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this report, including the information in the corporate presentation, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits 99.1 Corporate Presentation 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: November 27, 2024 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing